Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glargine insulin + liraglutide + metformin versus metformin + dapagliflozin + acarbose after short-term insulin pump intensive therapy in type 2 diabetes
ChiCTR2400084794Phase 4Completed
- Sponsor
- Guangrao County People's Hospital
- Start
- May 2024
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin glargine, liraglutide and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Guangrao County People's Hospital. Primary endpoints: Fasting blood glucose, Glycated hemoglobin and 1 more. Started May 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400084794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084794.